{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMHxg5ELDA","lastupdate":"2021-03-01T00:00:00.000Z","update_date":"2021-03-01T00:00:00.000Z","lastModified":"Jan 22, 2025","active":1,"confidence_score":88,"confidence_score_reason":"video or image, markets, external profiles, not claimed","urlname":"raziel-therapeutics","minimal_profile":null,"status":"","fullstatus":"","acquired":0,"hide_reason":null,"hide_reason_data":null,"hide_reasons":[{"id":"8257rxn4P8EFQOmS5hAAauHyYMhhxrA5u6yWX4XUShpybX3AMNo3Y9","reason":"Pending approval - External entity"},{"id":"aOIaOiiqfpA8UMw6VCTh8ueRmkG3lzDy1NGqEOaJbe11OrCzMTCCd6","reason":"The company is a service provider"},{"id":"ddgjKuc3GgH8E5UehSVJviRl471BCajL1plO8HtGoOojy2NivYqQ7x","reason":"Owner asked to delete"},{"id":"EjOKM211H1ira9J63oaGPuUxvr7Oba55TZo3NWsFO5uhbNu7o4x4zD","reason":"The company is not Israeli"},{"id":"J7fQJtnT3GdWWSE3MD8rzaW65LJ4jEIKxSZnneQiReONdZjG3zIqWe","reason":"Owner asked to hide in the meantime"},{"id":"NxlAC3ReFb5ksiYNLp2FnUyluoJzwRCYfcF7xpTZaPM53SdWQ5kv0B","reason":"Pending approval"},{"id":"RhC1tlwXzioK0MfzBII3H2wepEfQOfKVktmdwqeqTJjGi3ZaBWUqZo","reason":"The company is not innovative"},{"id":"S0Ed46vNI6vZYVxLedANWGjas23K6hY0QdsCtiGYL7lshqIEdLV3sA","reason":"The company ceased operations in Israel"},{"id":"VTANq7bEvlsEcPjp0ghelXfShaCosgndONGjgU730aAOxXtaDIF5j3","reason":"This is a product of an existing company"}],"type":"Startup","logokey":"$P3GbuOD9XFw9GoKo2PUPRi31Npy6XIvxxWAq7ure79j6378kd2YfOs","name":"Raziel Therapeutics","oneliner":"Injectable Drug for Treatment of Obesity","registrar":"514808955","website":"https://www.raziel-therapy.com","careerspage":"","founded_month":8,"founded_year":2012,"formernames":[],"sociallinks":{"twitter":"","youtube":"","facebook":"","linkedin":"","instagram":""},"social":[],"flattenedsociallinks":null,"apps":{"appstore":"","googleplay":""},"is_claimed_by_owner":null,"employees":"1-10","employees_exact":6,"patent":0,"raised":27100000,"stage":"C","public_stage":"C","primary_sector_key":"agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","primary_sector":"Health Tech & Life Sciences","alternativenames":["RT","Raziel Therapy"],"about":"Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for targeted fat reduction. The company has developed a new chemical entity that converts white adipose tissue (WAT) into brown adipose tissue (BAT) after a single injection into subcutaneous fat, potentially providing a new way to treat people who are overweight or obese.\r\n\r\nRaziels primary drug candidate is RZL-012, an injectable drug that is currently in preclinical development. RZL-012 is administered by several injections delivered in a single injection session. Once injected, RZL-012 triggers immediate fat-cell death, followed by a transient inflammatory process that lasts about a month during which necrotic fat tissue is replaced by fibrotic tissue. This results in a significant long-term, sustained shrinkage of fat tissue.\r\n\r\nThe companys products are based on work by the team led by Professor Muli Ben-Sasson, who discovered a family of compounds that are able to influence the fate of fat-tissue cells (adipocytes) and convert them from WAT to BAT tissues.\r\n\r\nIn November 2019, Raziel received FDA approval to develop RZL-012 as an orphan drug for Dercums disease.","climatetech_description":null,"is_climatetech_relevant":null,"phone":"+97289126940","country":null,"address":{"israeli":[{"id":"8fe3afd7-d032-4f92-8e8e-c5a151e529f3","city":"Rehovot","type":null,"address":"Prof. Menahem Plaut Street 10, Rehovot, Israel","placeid":null,"notactive":0,"openeddate":null,"registrarid":null,"firstrdcenter":0,"registrarname":null}],"officesabroad":null},"headquarter_address":null,"district":"Center District","news":[{"id":"VXQ3azaUEIpSkizZ7BVcaPnSw7OenkRutB01c80f6qGq2brHXor869","date":"Jul 15, 2025","link":"https://www.prnewswire.com/il/news-releases/365mc-and-raziel-therapeutics-announce-strategic-collaboration-to-accelerate-development-of-rzl-012-in-south-korea-302505353.html","source":"www.prnewswire.com","visible":1,"analysis":{"tags":"partnership","round":null,"company":"Raziel Therapeutics","layoffs":null,"summary":"365mc, a leading South Korean medical institution specializing in fat reduction, has partnered with Raziel Therapeutics, a clinical-stage biopharmaceutical company, to advance the development of RZL-012 in South Korea. RZL-012 is an injectable treatment for focal fat reduction, currently progressing toward Phase 3 trials. The collaboration will focus on clinical and commercial strategies, leveraging 365mcs expertise and market presence. Additionally, 365mc will make a strategic investment in Raziel Therapeutics, facilitated by Yozma Group, to support global expansion. This partnership aims to set a new standard in non-invasive body contouring, combining Raziels technology with 365mcs proprietary LAMS procedure.","partners":["365mc"],"customers":null,"eventType":null,"investors":"365mc","confidence":9,"key_topics":["partnership","clinical trials","fat reduction","global expansion","investment"],"date_of_event":null,"product_stage":"clinical trial","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners","Investment"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":"using","structuredIssuesShow":"#Product Stage  #Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"VjufNAC48XA5QjsOx2FEMfkgi8fgcz8haKK3dcpNaCaKRrWct9j1ie","news_summary":"/PRNewswire/ -- 365mc, South Korea's leading medical institution specializing in fat reduction treatments, and Raziel Therapeutics, a global clinical-stage...","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"a1f3ec37-9829-4f49-b288-bbb3e5a20831","date":"Sep 22, 2020","link":"https://www.calcalistech.com/ctech/articles/0,7340,L-3850958,00.html","source":"www.calcalistech.com","visible":1,"analysis":{"tags":"licensing deal","company":"Raziel Therapeutics Ltd.","layoffs":null,"summary":"Raziel Therapeutics has signed a major licensing deal with Chinas Fosun Pharma for milestone payments of up to $74 million. The agreement grants exclusive rights to Tianjin JuveStar Biotech, a company invested and incubated by Shanghai Fosun Pharmaceutical, to develop and commercialize Raziels RZL-012 compound in mainland China, Hong Kong, Macau, and Taiwan. RZL-012 is an injectable drug used for reducing double chins. Raziel Therapeutics will receive potential payments of $27 million before marketing approval, as well as additional potential sales milestone payments of up to $47 million and tiered royalty payments on future net sales. JuveStar will handle clinical studies, marketing, and sales, while Raziel will be responsible for manufacturing. The company has raised a total of $30 million to date.","partners":"Tianjin JuveStar Biotech Co., Ltd.","customers":null,"investors":"Pontifax, Catalyst Fund, Quark venture, Peregrine Investments, Wille AG","confidence":9,"key_topics":["licensing deal","RZL-012 compound","double chins","aesthetic treatment","Chinas Fosun Pharma"],"date_of_event":"2022-09-20","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"f9bJIYDzpSXlJugulWItZhOpKSxOtI7NN3jfu7GKSnMsSlp6GHnxNp","news_summary":"Double-chin reducing Israeli startup closes $74 million China licensing deal","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"9c356a56-f3f3-47f9-be2b-09301a27b91a","date":"Dec 18, 2019","link":"https://en.globes.co.il/en/article-fat-disorder-drug-co-raziel-therapeutics-raises-22m-1001311618","source":"en.globes.co.il","visible":1,"analysis":{"tags":"pharmaceutical, drug development","company":"Raziel Therapeutics","layoffs":null,"summary":"Raziel Therapeutics, an Israeli clinical-stage pharmaceutical company, has raised $22 million in a Series C financing round led by Pontifax. The company is developing a new drug, RZL-012, for aesthetic applications and fat disorders. The funds will support the Phase 2b development of RZL-012 for submental fat reduction and Dercums Disease. Raziel Therapeutics recently received FDA approval to develop RZL-012 as an orphan drug for Dercums disease patients. The company also announced the appointment of Philippe Schaison as chairman of the board of directors.","partners":null,"customers":null,"investors":"Pontifax, Dr. Shmuel Cabilly, Docor International, Catalyst Fund, Quark venture, Peregrine Investments, Wille AG","confidence":9,"key_topics":["Raziel Therapeutics","RZL-012","Series C financing","drug development","appointment of chairman"],"date_of_event":"December 18, 2019","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":"$22 million","structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"6WaHFut7bOLdbaHCR9hOiLgmQfE8OhSz8dsWrwRdrWICoJT1Faq5Bm","news_summary":"Fat disorder drug co Raziel Therapeutics raises $22m","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"1c954e39-bed0-4b20-8af2-c650c33a66eb","date":"Dec 10, 2018","link":"https://www.jpost.com/Special-Content/How-Israeli-Technology-is-Changing-Healthcare-574021","source":"www.jpost.com","visible":1,"analysis":{"tags":"healthcare, technology","company":"Raziel Therapeutics","layoffs":null,"summary":"The article discusses the advancements in healthcare technology in Israel, highlighting the role of investors, startups, and entrepreneurs. It mentions Raziel Therapeutics as a pioneering company that has developed fat melting injections. The injections supposedly melt fat cells and prevent fat cells from forming. Clinical trials indicate a reduction of up to 50% in fat after the first injection. The article also mentions researchers from the Weizmann Institute of Science who have discovered a molecule that regulates the renewing of damaged heart muscle cells. Additionally, an Israeli engineer has developed a nonintrusive method for screening newborns for autism using otoacoustic emissions. These advancements demonstrate the potential for effective and efficient results in healthcare.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["healthcare technology","health supplements","fat melting injections","damaged cell renewal","autism screening"],"date_of_event":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"J1avDYyzCm1cRdiQGqU9KHoqVxLHbpc451Pbnl95h6fR7BYZ88Vqnl","news_summary":"https://www.jpost.com/Special-Content/How-Israeli-Technology-is-Changing-Healthcare-574021","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"be8878a5-270d-4907-a69c-a066af2f7f3b","date":"Nov 29, 2017","link":"https://www.timesofisrael.com/israeli-fat-busting-shot-seeks-to-help-battle-obesity/","source":"www.timesofisrael.com","visible":1,"analysis":{"tags":"Healthcare, Obesity Treatment","company":"Raziel Therapeutics","layoffs":"Not mentioned","summary":"Raziel Therapeutics, an Israeli startup, has developed a fat-melting injection that destroys fat cells and delays their regeneration for up to nine months. The Jerusalem-based company claims that its product has a marked advantage over similar treatments. The injection is safer than surgery but needs to be part of a broader lifestyle change to be effective long-term. The company is funded by the Israel Innovation Authority, the Van Leer Technology Incubator, and Pontifax. The product is currently undergoing Phase 2a clinical testing in the US.","partners":"Not mentioned","customers":"Not mentioned","investors":["Israel Innovation Authority","Van Leer Technology Incubator","Pontifax"],"confidence":9,"key_topics":["Fat-melting Injection","Obesity Treatment","Clinical Trials","Market Potential","Lifestyle Change"],"date_of_event":"Not mentioned","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"Not mentioned","structured_issues":["Investment"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IafktV6PqcFQWU2Q2NP1LVGXQHJWysVtMZXPBZUJZBRoIsYgQiT5WW","news_summary":"Israeli 'fat-melting' injection claims to help battle obesity","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"4bdb93da-0546-4871-b240-5363573f8d0f","date":"Jul 20, 2016","link":"http://www.pontifax.com/portfolios/raziel-therapeutics/","source":"www.pontifax.com","visible":1,"analysis":{"tags":"Biopharma, MedTech","company":"Multiple Companies","layoffs":"Not Applicable","summary":"The article provides a list of companies in the biopharma and medtech sectors. Some of these companies are public, while others are private. A few have been acquired by larger companies. The companies are involved in a range of activities, from developing novel immunotherapies and cell-based therapies to creating innovative medical devices and gene therapies. The status of each company is also provided.","partners":"Not Applicable","customers":"Not Applicable","investors":"Not Applicable","confidence":10,"key_topics":"Biopharma, MedTech, Public Companies, Private Companies, Acquisitions","date_of_event":"Not Applicable","valuation_amount":"Not Applicable","impact_on_company":"Neutral","investment_amount":"Not Applicable","structured_issues":"None","acquisition_amount":"Not Applicable","structuredIssuesShow":"#None","entityGrowthIconPath":"none;"},"sentiment":"Neutral","analysisId":"7I8d5VCq1lEF1ZyHc8hLxiWnej64q7TYpPgaxchbUZUUA7atH0glT7","news_summary":"Portfolio - Pontifax Venture Capital","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"newsNumber":6,"techcommunityinvolvement":null,"mediagallery":[],"tags":["diabetes","therapeutics","drug-design","obesity","pharmaceuticals","treatments","chronic-patients","pharma-companies","orphan-drug","patients"],"classificationIDs":["agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"technologysuccessstory":[{"date":"2012-08-01","name":"Proprietary drug for targeted fat reduction","tags":["pharmaceuticals","drug-design","diabetes","therapeutics","treatments"],"category":"Pharmaceuticals & Diagnostics","tto_logo":"/image_cloud/yissum_tto_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6","university_logo":"/image_cloud/yissum_institution_logo_0151a5c5-6017-11e8-b269-41fdcbb0dda6"}],"usecases":[],"businessmodels":["B2B"],"productstage":"Clinical Trial","products":["RZL-012"],"geomarkets":["Israel","China"],"targetmarkets":[],"marketcapital":null,"marketcapitaldate":null,"funding":{"investors":9,"lastfunding":"Undisclosed","totalrounds":4,"fundingstage":"C","totalfunding":"$27.1M","publicinvestors":9,"lastpublicfunding":0,"totalpublicrounds":4,"totalpublicfunding":27100000},"team":[{"name":"Alon  Bloomenfeld","email":"alon@raziel-therapy.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgKHjvKcIDA","bounced":false,"claimed":0,"founder":0,"urlname":"alon-bloomenfeld-1","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICAwdOwkQkM","position":"CEO","last_name":"Bloomenfeld","claimtoken":"7ac72ce1b5b6a7511fabf68e7c0aade4d846afe35bbc4f6d6b3f00c1d1e2f826","first_name":"Alon ","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/alon-bloomenfeld-7b705821/","unsubscribed":false,"is_activeuser":1,"additionalemail":"alon.bloomenfeld@gmail.com","claimedemaildate":"2021-03-01 09:24:50.000000","initials":"AB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Eran Blaugrand","email":"eran@raziel-therapy.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4N7F2tAIDA","bounced":false,"claimed":0,"founder":0,"urlname":"eran-blaugrand","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgvrKlvwkM","position":"VP R&D","last_name":"Blaugrand","claimtoken":"b0a444e972310426293e7b69414f49f9a8ff35e7c194c308b63940fca03c4d38","first_name":"Eran","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/eran-blaugrund-213666106/","unsubscribed":false,"is_activeuser":1,"additionalemail":"elad@raziel-therapy.com","claimedemaildate":"2021-03-01 09:24:57.000000","initials":"EB","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Racheli Gueta","email":"racheli@raziel-therapy.com","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4N7F2tAKDA","bounced":false,"claimed":0,"founder":0,"urlname":"racheli-gueta","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDggYnthwgM","position":"Clinical Trials Manager","last_name":"Gueta","claimtoken":"43ff5b3bb047990d755c35c58207dae0e5e33898361d06bd85cf453447565542","first_name":"Racheli","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/racheli-gueta-6976721b/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":"2021-03-01 09:25:01.000000","initials":"RG","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"","visibilityTooltip":""}],"description_edited":1,"tag_line_edited":1,"sector":"Pharmaceuticals","sectorverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgLHD0KwIDA","fullname":"Sharon Shapira"},"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgPGylJ0IDA","fullname":"Natalia Golczar"},"biverifydate":"2019-12-19T00:00:00.000Z","crunchbaseid":"raziel-therapeutics","lastupdator":"Paul Weisko","lastupdator_email":"pweisko@gmail.com","creator":"Alyssa Williams","creator_email":"williamsar95@gmail.com","createdate":"2015-08-03T00:00:00.000Z","biverification":"Natalia Golczar","sectorverification":"Sharon Shapira","affiliatedOrganizations":null,"timeline":[{"id":"X7pJzWXMdpYjeKFtmUd0IewwGwYQs4d8FkkQ1N7gC8J7V47uyP18Lq","date":"Dec 2024","amount":"Undisclosed","source":"Amit, Peregrine","eventtype":"FundingRoundEvent","investment":[{"name":"Peregrine Ventures","type":"Investor","amount":212000,"hidden":false,"country":"Israel","fullurl":"/investor_page/peregrine-ventures","logokey":"$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","tagline":null,"urlname":"/investor_page/peregrine-ventures","isisraeli":1,"investorid":"Y57DaSxuoKU94wasDhLnfv7mvfy2Gyr9ekuOlM6BCGtWak5CprFY2M","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"wChCYERwV5SccCBhuOBQwZv7IQk71sZ0IxjepF08lMa368axpBBTCD","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"SAFE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC6j5iMCgw","date":"Dec 2019","amount":"$22M","source":"https://en.globes.co.il/en/article-fat-disorder-drug-co-raziel-therapeutics-raises-22m-1001311618","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"948dcb8e-34a9-4bb2-bc0b-ba397413828c","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"Lead ","followupcaption":"Follow on "},{"name":"Quark Venture","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/quark-venture","logokey":"$YqTloV7jHhFJJgexhl8uKOwKGRlphv3Hg6jIB4VrIT6PyOv9oLRWLH","tagline":"","urlname":"/investor_page/quark-venture","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCUwsWJCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0e02d1f8-b68b-4fcd-93ee-570ca045a7f3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YqTloV7jHhFJJgexhl8uKOwKGRlphv3Hg6jIB4VrIT6PyOv9oLRWLH","leadcaption":"","followupcaption":""},{"name":"Docor International Management","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/docor","logokey":"$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","tagline":null,"urlname":"/investor_page/docor","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnYj5YKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"3c60fb1c-d3f5-4f7e-9cb2-49a0f5adc6cb","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","leadcaption":"","followupcaption":"Follow on "},{"name":"Catalyst","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/catalyst","logokey":"$Ll8LUDoRfAWWehpQhBeNDQdO1vtlDBbbTGmOvsBQd2dkOMY0wHaHHt","tagline":null,"urlname":"/investor_page/catalyst","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJG2-IgKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"815cdb62-a036-4664-8797-656ef1b5a040","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Ll8LUDoRfAWWehpQhBeNDQdO1vtlDBbbTGmOvsBQd2dkOMY0wHaHHt","leadcaption":"","followupcaption":""},{"name":"Wille AG","type":"Other","amount":0,"hidden":false,"country":"Switzerland","fullurl":"/company_page/wille-ag","logokey":"$9KJSpnWBAB98x3B7V3gBsytpoHb31N94M2u7jjjPmCpGhzEnOV3PMY","tagline":"","urlname":"/company_page/wille-ag","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODGoJ-GCAw","fundingtype":"Other","leadpartner":null,"investmentid":"bfa360d6-e714-43a6-89f4-8d067d7eb399","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9KJSpnWBAB98x3B7V3gBsytpoHb31N94M2u7jjjPmCpGhzEnOV3PMY","leadcaption":"","followupcaption":""},{"name":null,"type":null,"amount":0,"hidden":false,"country":"Israel","fullurl":null,"logokey":null,"tagline":null,"urlname":null,"isisraeli":null,"investorid":null,"fundingtype":"Angel","leadpartner":null,"investmentid":"db95aa79-86e9-4adb-b306-66293e43aa30","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/empty-state.svg","leadcaption":"","followupcaption":""},{"name":"Shmuel Cabilly","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/shmuel-cabilly","logokey":"$ByIlkmN3MYiCH7QjUV39OpRbruBOVERDtnhhy0CbRHNXVpR1IMQo4F","tagline":null,"urlname":"/investor_page/shmuel-cabilly","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkJjNp-MLDA","fundingtype":"Angel","leadpartner":null,"investmentid":"dd25dcc5-76d6-4e09-ab7b-225065718d16","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ByIlkmN3MYiCH7QjUV39OpRbruBOVERDtnhhy0CbRHNXVpR1IMQo4F","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":22000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODElY3qCQw","date":"Feb 2016","amount":"$4.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"32b6498f-eb39-40c2-b851-955a8c5f90a6","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""},{"name":"Docor International Management","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/docor","logokey":"$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","tagline":null,"urlname":"/investor_page/docor","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnYj5YKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d32d7946-f621-4b12-ab90-39172d36676f","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":4500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODk_PffCAw","date":"Dec 2014","amount":"$600K","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"VLX Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vlx","logokey":"$dXu7ZEAH5LAowXCtVDAvI4T3opiaicfOFgluzyyEJuZioaeoMbfNc4","tagline":null,"urlname":"/investor_page/vlx","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgLHYycwJDA","fundingtype":"Incubator","leadpartner":null,"investmentid":"5d89494d-0a38-4682-b445-a0136283da64","fundingsubtype":"Incubator","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dXu7ZEAH5LAowXCtVDAvI4T3opiaicfOFgluzyyEJuZioaeoMbfNc4","leadcaption":"","followupcaption":""},{"name":"Israel Innovation Authority","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"89691e78-02a0-4446-a9b2-49d9d2e8ff50","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"investmentstage":[],"exits":[],"investments":[],"portfolio":[],"funds":[],"founded":"8/2012","databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"","fundingtype":"Startup","parsedName":"Raziel Therapeutics","logourl":"https://storage.googleapis.com/clean-finder-353810/$P3GbuOD9XFw9GoKo2PUPRi31Npy6XIvxxWAq7ure79j6378kd2YfOs","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$P3GbuOD9XFw9GoKo2PUPRi31Npy6XIvxxWAq7ure79j6378kd2YfOs","seoabout":"Raziel Therapeutics is a clinical-stage pharmaceutical company developing a proprietary drug for targeted fat reduction. The company has developed a new ch...","seoTitle":"Israeli Startup","solutions":[],"teamMembersNumber":3,"primarySector":"Health Tech & Life Sciences","primary-sector-display":"block","classifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"},{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"},{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationDelimited":["IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA>Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","TechnologyClassificationModel>Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA>Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA>Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA"],"classificationsViewModel":"|0:>IndustryClassificationModel|1:>IndustryClassificationModel/Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Healthcare#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA/Patients#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA|2:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA/Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA|3:>IndustryClassificationModel>Healthcare & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA>Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA/Pharmaceuticals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA|0:>TechnologyClassificationModel|1:>TechnologyClassificationModel/Biologicals#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA|0:>SectorClassificationModel|1:>SectorClassificationModel/Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA|2:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA/Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA|3:>SectorClassificationModel>Health Tech & Life Sciences#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA>Pharma & Medical Biotechnology#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA/Drugs Discovery & Development#agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA|","classificationTrees":{"sector":[{"title":"Health Tech & Life Sciences","key":"0-0","path":"SectorClassificationModel>Health Tech & Life Sciences","children":[{"title":"Pharma & Medical Biotechnology","key":"0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology","children":[{"title":"Drugs Discovery & Development","key":"0-0-0-0","path":"SectorClassificationModel>Health Tech & Life Sciences>Pharma & Medical Biotechnology>Drugs Discovery & Development"}]}]}],"targetCustomer":[{"title":"Healthcare & Life Sciences","key":"0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences","children":[{"title":"Healthcare","key":"0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare","children":[{"title":"Patients","key":"0-0-0-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Healthcare>Patients"}]},{"title":"Life Sciences","key":"0-0-1","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences","children":[{"title":"Pharmaceuticals","key":"0-0-1-0","path":"IndustryClassificationModel>Healthcare & Life Sciences>Life Sciences>Pharmaceuticals"}]}]}],"coreTechnology":[{"title":"Biologicals","key":"0-0","path":"TechnologyClassificationModel>Biologicals"}]},"sectorClassifications":[{"depth":0,"name":"Sector","queryString":"sectorclassification=undefined","classificationName":"sectorclassification"},{"depth":1,"name":"Health Tech & Life Sciences","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LuwgtgKDA","classificationName":"sectorclassification"},{"depth":2,"name":"Pharma & Medical Biotechnology","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Lu-rdMJDA","classificationName":"sectorclassification"},{"depth":3,"name":"Drugs Discovery & Development","queryString":"sectorclassification=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Iety_cIDA","classificationName":"sectorclassification"}],"coreTechnologyClassifications":[{"depth":0,"name":"Core Technology","queryString":"coretechnology=undefined","classificationName":"coretechnology"},{"depth":1,"name":"Biologicals","queryString":"coretechnology=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Ie8rfEJDA","classificationName":"coretechnology"}],"targetCustomerClassifications":[{"depth":0,"name":"Target Customer","queryString":"targetcustomer=undefined","classificationName":"targetcustomer"},{"depth":1,"name":"Healthcare & Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4If8nsIKDA","classificationName":"targetcustomer"},{"depth":2,"name":"Healthcare","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Puah5IIDA","classificationName":"targetcustomer"},{"depth":3,"name":"Patients","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4PuD2a4JDA","classificationName":"targetcustomer"},{"depth":2,"name":"Life Sciences","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4LunvfsLDA","classificationName":"targetcustomer"},{"depth":3,"name":"Pharmaceuticals","queryString":"targetcustomer=agxzfmlsbGlzdHNpdGVyJAsSF0Jhc2VDbGFzc2lmaWNhdGlvbk1vZGVsGICA4Kv1pZ8LDA","classificationName":"targetcustomer"}],"classificationNames":{"sector":["Health Tech & Life Sciences","Pharma & Medical Biotechnology","Drugs Discovery & Development"],"coreTechnology":["Biologicals"],"targetCustomer":["Healthcare & Life Sciences","Healthcare","Patients","Life Sciences","Pharmaceuticals"]},"section":null,"sectionParams":"","queryParams":"","popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none","climateTag":"none","seeMoreSimilarCompanisDisplay":"none","similarCompaniesTitleFontSize":"3.2rem","similarCompaniesTitle":"Similar Companies","similar_companies":[]},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[{"id":"X7pJzWXMdpYjeKFtmUd0IewwGwYQs4d8FkkQ1N7gC8J7V47uyP18Lq","date":"Dec 2024","amount":"Undisclosed","source":"Amit, Peregrine","eventtype":"FundingRoundEvent","investment":[{"name":"Peregrine Ventures","type":"Investor","amount":212000,"hidden":false,"country":"Israel","fullurl":"/investor_page/peregrine-ventures","logokey":"$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","tagline":null,"urlname":"/investor_page/peregrine-ventures","isisraeli":1,"investorid":"Y57DaSxuoKU94wasDhLnfv7mvfy2Gyr9ekuOlM6BCGtWak5CprFY2M","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"wChCYERwV5SccCBhuOBQwZv7IQk71sZ0IxjepF08lMa368axpBBTCD","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$T9b3MhmeKbyWXOhmHsdeo59IpRH5j3rFLwfog4x6rVvePI0vqruN3t","investmentVisibilityClassName":"","investmentVisibilityTooltip":"","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":null,"fundingvisibility":"Public","fundingtypefundingtype":"SAFE","style":"","hiddenCompanyTooltip":"","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","sectionname":"Private Equity Funding","amountnumber":null,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOC6j5iMCgw","date":"Dec 2019","amount":"$22M","source":"https://en.globes.co.il/en/article-fat-disorder-drug-co-raziel-therapeutics-raises-22m-1001311618","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"948dcb8e-34a9-4bb2-bc0b-ba397413828c","fundingsubtype":"VC and Private Equity","investorislead":1,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"Lead ","followupcaption":"Follow on "},{"name":"Quark Venture","type":"Investor","amount":0,"hidden":false,"country":"Canada","fullurl":"/investor_page/quark-venture","logokey":"$YqTloV7jHhFJJgexhl8uKOwKGRlphv3Hg6jIB4VrIT6PyOv9oLRWLH","tagline":"","urlname":"/investor_page/quark-venture","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOCUwsWJCAw","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"0e02d1f8-b68b-4fcd-93ee-570ca045a7f3","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$YqTloV7jHhFJJgexhl8uKOwKGRlphv3Hg6jIB4VrIT6PyOv9oLRWLH","leadcaption":"","followupcaption":""},{"name":"Docor International Management","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/docor","logokey":"$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","tagline":null,"urlname":"/investor_page/docor","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnYj5YKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"3c60fb1c-d3f5-4f7e-9cb2-49a0f5adc6cb","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":1,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","leadcaption":"","followupcaption":"Follow on "},{"name":"Catalyst","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/catalyst","logokey":"$Ll8LUDoRfAWWehpQhBeNDQdO1vtlDBbbTGmOvsBQd2dkOMY0wHaHHt","tagline":null,"urlname":"/investor_page/catalyst","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgJG2-IgKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"815cdb62-a036-4664-8797-656ef1b5a040","fundingsubtype":"VC and Private Equity","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$Ll8LUDoRfAWWehpQhBeNDQdO1vtlDBbbTGmOvsBQd2dkOMY0wHaHHt","leadcaption":"","followupcaption":""},{"name":"Wille AG","type":"Other","amount":0,"hidden":false,"country":"Switzerland","fullurl":"/company_page/wille-ag","logokey":"$9KJSpnWBAB98x3B7V3gBsytpoHb31N94M2u7jjjPmCpGhzEnOV3PMY","tagline":"","urlname":"/company_page/wille-ag","isisraeli":0,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODGoJ-GCAw","fundingtype":"Other","leadpartner":null,"investmentid":"bfa360d6-e714-43a6-89f4-8d067d7eb399","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$9KJSpnWBAB98x3B7V3gBsytpoHb31N94M2u7jjjPmCpGhzEnOV3PMY","leadcaption":"","followupcaption":""},{"name":null,"type":null,"amount":0,"hidden":false,"country":"Israel","fullurl":null,"logokey":null,"tagline":null,"urlname":null,"isisraeli":null,"investorid":null,"fundingtype":"Angel","leadpartner":null,"investmentid":"db95aa79-86e9-4adb-b306-66293e43aa30","fundingsubtype":null,"investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"/assets/empty-state.svg","leadcaption":"","followupcaption":""},{"name":"Shmuel Cabilly","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/shmuel-cabilly","logokey":"$ByIlkmN3MYiCH7QjUV39OpRbruBOVERDtnhhy0CbRHNXVpR1IMQo4F","tagline":null,"urlname":"/investor_page/shmuel-cabilly","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAkJjNp-MLDA","fundingtype":"Angel","leadpartner":null,"investmentid":"dd25dcc5-76d6-4e09-ab7b-225065718d16","fundingsubtype":"Angel","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$ByIlkmN3MYiCH7QjUV39OpRbruBOVERDtnhhy0CbRHNXVpR1IMQo4F","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"C Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":22000000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODElY3qCQw","date":"Feb 2016","amount":"$4.5M","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"Pontifax","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/Pontifax","logokey":"$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","tagline":null,"urlname":"/investor_page/Pontifax","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgOfWjoAKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"32b6498f-eb39-40c2-b851-955a8c5f90a6","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$8HWp0ziD5Hcmj6wqEIHQTrElz5KthIPEOZM39F7kKUQRFzC0JbmnmH","leadcaption":"","followupcaption":""},{"name":"Docor International Management","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/docor","logokey":"$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","tagline":null,"urlname":"/investor_page/docor","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgMnYj5YKDA","fundingtype":"VC and Private Equity","leadpartner":null,"investmentid":"d32d7946-f621-4b12-ab90-39172d36676f","fundingsubtype":"VC and Private Equity","investorislead":null,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$OfHtk8MQpXyjuEfISyRNC2I0FArnwi7SC4uowUIF3xWUco4YnAg2VW","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"A Round","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":4500000,"capitalraised":"Undisclosed","valuation":"Undisclosed"},{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgODk_PffCAw","date":"Dec 2014","amount":"$600K","source":"Migrated","eventtype":"FundingRoundEvent","investment":[{"name":"VLX Ventures","type":"Investor","amount":0,"hidden":false,"country":"Israel","fullurl":"/investor_page/vlx","logokey":"$dXu7ZEAH5LAowXCtVDAvI4T3opiaicfOFgluzyyEJuZioaeoMbfNc4","tagline":null,"urlname":"/investor_page/vlx","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgLHYycwJDA","fundingtype":"Incubator","leadpartner":null,"investmentid":"5d89494d-0a38-4682-b445-a0136283da64","fundingsubtype":"Incubator","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$dXu7ZEAH5LAowXCtVDAvI4T3opiaicfOFgluzyyEJuZioaeoMbfNc4","leadcaption":"","followupcaption":""},{"name":"Israel Innovation Authority","type":"Government","amount":0,"hidden":false,"country":"Israel","fullurl":"/company_page/israel-innovation-authority-4","logokey":"$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","tagline":"","urlname":"/company_page/israel-innovation-authority-4","isisraeli":1,"investorid":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgOC20eTwCQw","fundingtype":"Government","leadpartner":null,"investmentid":"89691e78-02a0-4446-a9b2-49d9d2e8ff50","fundingsubtype":"","investorislead":0,"amountvisibility":"Public","isextensionround":0,"leadpartneruserid":null,"investorisfollowon":0,"investorvisibility":"Public","leadpartnermemberid":null,"investmentVisibilityClassName":"","investmentVisibilityTooltip":"","blurFinancialData":"","style":"","hiddenCompanyTooltip":"","logourl":"https://storage.googleapis.com/clean-finder-353810/$5c4LgWLzukZDi2b9IlcK1cbez0QSOoXpTLU21Y4ByNtfkRvqOSLs8L","leadcaption":"","followupcaption":""}],"eventvisibility":"Public","amountvisibility":"Public","fundingvisibility":"Public","fundingtypefundingtype":"Seed","fundingvisibilityClassName":"","fundingvisibilityTooltip":"","amountvisibilityClassName":"","amountvisibilityTooltip":"","token_visibilityClassName":"","token_visibilityTooltip":"","style":"","hiddenCompanyTooltip":"","sectionname":"Private Equity Funding","amountnumber":600000,"capitalraised":"Undisclosed","valuation":"Undisclosed"}],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}